Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Combination treatment

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Approximately half of those with Sjögren’s disease are thought to be undiagnosed

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

- PMLiVE

Merck announces agreement with US government to reduce prices of prescription medication

The pharma company will invest more than $70bn in the US to boost production and innovation

Healthcare setting

Clinical research in 2026: The trends shaping tomorrow

Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.

Cuttsy + Cuttsy

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

- PMLiVE

5 key digital CX challenges in pharma, and how to start solving them

Creating great digital experiences in pharma isn’t easy, but progress doesn’t always need to come from big projects or budgets. Here are 5 common challenges that leading digital teams are...

Graphite Digital

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Novartis announces plans for new US manufacturing hub

The US hub is expected to create 700 new jobs by 2030

- PMLiVE

Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE

Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links